Human NKG2A, recombinant (N-8His)

Human NKG2A, recombinant (N-8His)
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
NOV-CB20.10ug 10 µg - -

10 - 15 Werktage*

30,00 €
NOV-CB20.50ug 50 µg - -

10 - 15 Werktage*

90,00 €
NOV-CB20.500ug 500 µg - -

10 - 15 Werktage*

600,00 €
NOV-CB20.1mg 1 mg - -

10 - 15 Werktage*

950,00 €
 
Recombinant Human NKG2-A/NKG2-B Type II Integral Membrane Protein is produced by our Mammalian... mehr
Produktinformationen "Human NKG2A, recombinant (N-8His)"
Recombinant Human NKG2-A/NKG2-B Type II Integral Membrane Protein is produced by our Mammalian expression system and the target gene encoding Arg100-Leu233 is expressed with a 8His tag at the N-terminus. Protein function: Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self (PubMed:9486650, PubMed:18083576, PubMed:9430220). Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules (PubMed:9485206, PubMed:12165520). Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions (PubMed:9486650, PubMed:9430220, PubMed:9485206, PubMed:30860984). Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen- driven response to avoid autoimmunity (PubMed:12387742). On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens (PubMed:18064301). In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion (PubMed:30503213, PubMed:30860984). [The UniProt Consortium]
Schlagworte: KLRC1, CD159a, NK cell receptor A, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, NKG2-A/NKG2-B type II integral membrane protein, Recombinant Human NKG2A (N-8His)
Hersteller: Novoprotein
Hersteller-Nr: CB20

Eigenschaften

Konjugat: No
Wirt: Human cells
Spezies-Reaktivität: human
MW: 16.5 kD
Format: Lyophilized

Datenbank Information

KEGG ID : K06541 | Passende Produkte
UniProt ID : P26715 | Passende Produkte

Handhabung & Sicherheit

Lagerung: -20°C (+4 °C for short term storage)
Versand: +20°C (International: +20°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier folgen Informationen zur Produktreferenz. mehr
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Human NKG2A, recombinant (N-8His)"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen